# Filterlex Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/filterlex-medical

- Industry: Medical Devices & Equipment
- Headquarters: Israel
- Website: www.filterlex.com
- Total disclosed funding: $3M
- Latest round: Series A (Jul 15, 2019)
- Investors on record: 2

## About

Filterlex Medical Ltd. specializes in the development of advanced medical devices that provide full-body embolic protection during catheter-based heart procedures, focusing on enhancing patient safety and procedural effectiveness.Founded in 2015 and headquartered in Israel, Filterlex Medical Ltd. focuses on innovative solutions for cardiovascular interventions. The company was established by Eyal Teichman, who has experience in founding other medical technology companies. Filterlex has successfully raised EUR 7 million in its latest funding round on December 21, 2021, led by the European Innovation Council, bringing the total amount raised to EUR 7 million across 6 deals.Filterlex Medical specializes in advanced medical devices designed for full-body embolic protection during catheter-based structural heart procedures, particularly Transcatheter Aortic Valve Implantation (TAVI). Its flagship product, the CAPTIS® device, uniquely integrates a triple-action mechanism that deflects, captures, and removes embolic particles, mitigating the risk of complications such as stroke and acute kidney injury. The device is deployed through the aorta and offers seamless integration with existing procedural workflows, ensuring it does not interfere with other devices used during surgery. Filterlex's products primarily serve cardiovascular hospitals and medical centers around the globe, with a focus on Europe and North America, addressing critical unmet needs in TAVI procedures.Filterlex Medical generates revenue through the sales of its CAPTIS® embolic protection device directly to hospitals and healthcare providers. The sales model is structured around direct business-to-business transactions, facilitating partnerships with medical institutions that utilize the device during TAVI procedures. These transactions may involve bulk purchases or contractual agreements for usage based on procedural volume. The company has secured substantial funding to support its clinical programs and product development, reinforcing its market presence and expanding its client base. The revenue model is primarily transactional, focusing on device sales rather than subscriptions or recurring service fees.Filterlex Medical plans to utilize the EUR 7 million raised in its latest funding round to support its clinical program expansion, regulatory approvals, and commercialization of the CAPTIS® full-body embolic protection system. The company is focused on developing new products and expanding its reach into additional markets, particularly targeting growth in regions with increasing demand for advanced medical solutions. Specific timelines or product launch dates have not been disclosed.

## Funding rounds

- Series A, Jul 15, 2019, $3M — Besadno, Alon Medtech Ventures

## Investors

- Besadno (https://capitalatlas.ai/funds/besadno) — Series A
- Alon Medtech Ventures — Series A